Abstract | INTRODUCTION: Diabetes is a chronic disease associated with high morbidity and mortality, which represents a major public health concern. Interventions that can enhance patient care and reduce clinic visits will not only relieve some of this burden, they will also improve patient QOL and wellbeing. AIMS: EVIDENCE REVIEW: CLINICAL VALUE:
Insulin glargine has established itself as a first-line choice in patients with type 1 diabetes, including children (>6 years) and adolescents, and is a recommended treatment option. In patients with type 2 diabetes it is clearly associated with less hypoglycemia than NPH insulin, and this may help overcome one of the major barriers to starting insulin therapy in this class of patient. Thus, insulin glargine is a valuable addition to the therapeutic armamentarium available to physicians and it has the potential to significantly improve the quality of life of patients with diabetes.
|
Authors | Rhian Clissold, Steve Clissold |
Journal | Core evidence
(Core Evid)
Vol. 2
Issue 2
Pg. 89-110
(Nov 30 2007)
ISSN: 1555-1741 [Print] New Zealand |
PMID | 21221178
(Publication Type: Journal Article)
|